Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report

Anaplastic lymphoma kinase (ALK) rearrangement is extremely rare in lung squamous cell carcinoma (LSCC), and it remains controversial as to whether LSCC patients with ALK rearrangement can benefit from ALK tyrosine kinase inhibitors (TKIs). Here, we report an LSCC patient with ALK rearrangement who...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Bin, Han, Xue, Pang, Linrong, Xu, Caihong, Liu, Sisi, Cheng, Xiaochun, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349191/
https://www.ncbi.nlm.nih.gov/pubmed/34376997
http://dx.doi.org/10.2147/OTT.S315832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349191/
https://www.ncbi.nlm.nih.gov/pubmed/34376997
http://dx.doi.org/10.2147/OTT.S315832

Ejemplares similares